BenevolentAI

BenevolentAI builds and applies AI to transform the way medicines are discovered and developed. The company's Benevolent Platform integrates and analyzes vast biomedical datasets using knowledge graphs and NLP to generate novel insights for drug discovery and drug repurposing. BenevolentAI gained widespread recognition for its AI-driven identification of baricitinib as a potential COVID-19 treatment, which was subsequently validated in clinical trials and received emergency authorization.

The Benevolent Platform integrates structured and unstructured biomedical data into a knowledge graph, using NLP and machine learning to identify novel drug targets, predict mechanisms of disease, and find drug repurposing opportunities.